Patient Clinical T stage Clinical N stage Site Criteria Factor No. of cycle RECIST response Surgery Pathologic T stage Pathologic N stage Pathologic response Surgical margin
1 4 1 H BR SMA 4 SD SSPPD 3 1 IIa R0
2 3 0 H BR SMV 4 PR SSPPD/SMVR 3 0 IIa R0
3 1 0 H R - 2 SD SSPPD 1 0 I R0
4 3 0 H R - 2 SD SSPPD 3 1 I R0
5 3 0 H BR SMV 2 SD SSPPD/SMVR 3 0 I R0
6 3 1 T R - 11 PR DP 3 1 IIa R0
7 3 0 H R - 2 SD Lap-PD 3 1 IIa R0
8 3 0 H R - 2 SD Lap-SSPPD 3 0 IIa R1
9 4 0 H BR SMV/SMA 3 PR Lap-SSPPD/SMVR 1 0 IIa R0
10 3 0 H BR SMV 4 SD Lap-SSPPD/SMVR 3 1 IIa R0
11 3 0 H R - 2 SD Lap-SSPPD 3 0 IIa R0
Abbreviations: RECIST- Response Evaluation Criteria In Solid Tumors; H- Head of Pancreas; T- Tail of Pancreas; SMA- Superior Mesenteric Artery; SMV- Superior Mesenteric Vein; SD- Stable Disease; PR- Partial Response; SSPPD- Subtotal Stomach Preserving Pancreaticoduodenectomy; SMVR- Superior Mesenteric Vein Resection; DP- Distal Pancreatectomy; Lap-PD- Laparoscopic Pancreaticoduodenectomy; Lap-SSPPD- Laparoscopic Subtotal Stomach Preserving Pancreaticoduodenectomy
Table 4: Clinical characteristics of patients who underwent pancreatic resection after neoadjuvant chemotherapy with gemcitabine and S1.